Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®).
Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, Hans DB; FRAX(®) Position Development Conference Members. Leib ES, et al. Among authors: geusens pp. J Clin Densitom. 2011 Jul-Sep;14(3):212-9. doi: 10.1016/j.jocd.2011.05.014. J Clin Densitom. 2011. PMID: 21810527
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.
Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP. Watts NB, et al. Among authors: geusens pp. J Bone Miner Res. 2009 Oct;24(10):1643-6. doi: 10.1359/jbmr.090818. J Bone Miner Res. 2009. PMID: 19712042 Free article. No abstract available.
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF. Saag KG, et al. Lancet Diabetes Endocrinol. 2018 Jun;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5. Epub 2018 Apr 6. Lancet Diabetes Endocrinol. 2018. PMID: 29631782 Clinical Trial.
Falls and fractures in postmenopausal women: a review.
Geusens P, Milisen K, Dejaeger E, Boonen S. Geusens P, et al. J Br Menopause Soc. 2003 Sep;9(3):101-6. doi: 10.1258/136218003100322314. J Br Menopause Soc. 2003. PMID: 14670194 Review.
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CA, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, López-Romero P, Fahrleitner-Pammer A. Geusens P, et al. J Bone Miner Res. 2018 May;33(5):783-794. doi: 10.1002/jbmr.3384. Epub 2018 Feb 9. J Bone Miner Res. 2018. PMID: 29329484 Free article. Clinical Trial.
244 results